Marketdash
Back to News

Shattuck Labs Gets Upgrade as Analysts Bet on Different Approach to Inflammatory Bowel Disease

MarketDash Editorial Team
6 days ago
HC Wainwright sees opportunity for Shattuck Labs' SL-325 to capture IBD market share by targeting the DR3 receptor instead of the TL1A ligand, potentially avoiding durability issues plaguing competitors.

Sometimes the best strategy is to attack the problem from the opposite direction. That's the bet HC Wainwright is making on Shattuck Labs Inc. (STTK), upgrading the biotech from Neutral to Buy with a $6 price target on Monday.

The thesis centers on SL-325, Shattuck's lead candidate for inflammatory bowel disease. While Big Pharma has been busy blocking the TL1A ligand with varying degrees of success, Shattuck is targeting the other end of the pathway—the DR3 receptor itself.

The company dosed its first healthy volunteers in the single-ascending dose portion of the Phase 1 trial during the third quarter of 2025. Both the single-ascending dose and multiple-ascending dose portions should wrap up enrollment by the second quarter of 2026.

"We see an opportunity for SL-325 to enter and take up significant market share," analyst Joseph Pantginis wrote on Monday. That's a bold statement considering the crowded field, but the upgrade hinges on what might be cracks forming in the leading approaches.

The TL1A Problem Nobody Wants to Talk About

The TL1A/DR3 pathway has become the hot target for treating inflammatory bowel disease, including ulcerative colitis and Crohn's Disease. Big players like Merck & Co. Inc. (MRK) with tulisokibart and Roche Holdings AG (RHHBY) with afimkibart are leading late-stage programs that block TL1A directly, and the data has been encouraging so far.

But here's the issue: immunogenicity keeps popping up. When the body develops anti-drug antibodies, treatment durability suffers. It's a common constraint across the TL1A-blocking class, and it's creating an opening for someone who can solve the problem differently.

Why Targeting the Receptor Might Work Better

Historically, blocking receptors has been trickier than blocking soluble ligands like TL1A. That's why everyone went for the ligand approach first—it's the easier path. But Shattuck's antibody-engineering capabilities have allowed it to effectively antagonize DR3 where others have struggled.

The biological logic is straightforward. DR3 is constitutively expressed, meaning it's always there on cells. TL1A, on the other hand, only shows up transiently when inflammation kicks into gear in the gut. Block the receptor that's always present, and you might get more durable inflammatory control than chasing a ligand that comes and goes.

It's the kind of biological reasoning that sounds great in theory—now Shattuck needs to prove it works in practice. The stock certainly liked the analyst's confidence, climbing 13.3% to $2.38 on Monday.

Back to News

Shattuck Labs Gets Upgrade as Analysts Bet on Different Approach to Inflammatory Bowel Disease

MarketDash Editorial Team
6 days ago
HC Wainwright sees opportunity for Shattuck Labs' SL-325 to capture IBD market share by targeting the DR3 receptor instead of the TL1A ligand, potentially avoiding durability issues plaguing competitors.

Sometimes the best strategy is to attack the problem from the opposite direction. That's the bet HC Wainwright is making on Shattuck Labs Inc. (STTK), upgrading the biotech from Neutral to Buy with a $6 price target on Monday.

The thesis centers on SL-325, Shattuck's lead candidate for inflammatory bowel disease. While Big Pharma has been busy blocking the TL1A ligand with varying degrees of success, Shattuck is targeting the other end of the pathway—the DR3 receptor itself.

The company dosed its first healthy volunteers in the single-ascending dose portion of the Phase 1 trial during the third quarter of 2025. Both the single-ascending dose and multiple-ascending dose portions should wrap up enrollment by the second quarter of 2026.

"We see an opportunity for SL-325 to enter and take up significant market share," analyst Joseph Pantginis wrote on Monday. That's a bold statement considering the crowded field, but the upgrade hinges on what might be cracks forming in the leading approaches.

The TL1A Problem Nobody Wants to Talk About

The TL1A/DR3 pathway has become the hot target for treating inflammatory bowel disease, including ulcerative colitis and Crohn's Disease. Big players like Merck & Co. Inc. (MRK) with tulisokibart and Roche Holdings AG (RHHBY) with afimkibart are leading late-stage programs that block TL1A directly, and the data has been encouraging so far.

But here's the issue: immunogenicity keeps popping up. When the body develops anti-drug antibodies, treatment durability suffers. It's a common constraint across the TL1A-blocking class, and it's creating an opening for someone who can solve the problem differently.

Why Targeting the Receptor Might Work Better

Historically, blocking receptors has been trickier than blocking soluble ligands like TL1A. That's why everyone went for the ligand approach first—it's the easier path. But Shattuck's antibody-engineering capabilities have allowed it to effectively antagonize DR3 where others have struggled.

The biological logic is straightforward. DR3 is constitutively expressed, meaning it's always there on cells. TL1A, on the other hand, only shows up transiently when inflammation kicks into gear in the gut. Block the receptor that's always present, and you might get more durable inflammatory control than chasing a ligand that comes and goes.

It's the kind of biological reasoning that sounds great in theory—now Shattuck needs to prove it works in practice. The stock certainly liked the analyst's confidence, climbing 13.3% to $2.38 on Monday.